Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Azienda Ospedaliero-Universitaria Careggi | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Currently, in the treatment of bladder cancer the use of robotics has entered in clinical practice, therefor robotic radical cystectomy with or without reconstruction is offered to patients during counseling procedures, if deemed appropriate and possible. The aim of the study is therefore the long-term evaluation of the peri-post-operative, oncological and functional results of patients undergoing radical cystectomy, both with an open and robotic approach. This study will thus help to clarify the actual impact of robotic surgery
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Radical Cystectomy | Patients who underwent radical cystectomy for bladder cancer in our centre |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Radical Cystectomy | Procedure | All the patients enrolled have undergone or will undergo radical cystectomy, with or without lymphadenectomy or urethrectomy All possibles urinary diversion are included, like ileal conduit, neobladder etc... |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants who will die from bladder cancer | Bladder Cancer Specific Mortality after surgery | From enrollment to late follow-up, up to 7 years |
| Number of participants who will experience bladder cancer recurrence | Bladder Cancer Recurrence | From enrollment to late follow-up, up to 7 years |
| Number of participants who will die from all causes | All cause mortality after surgery | From enrollment to late follow-up, up to 7 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants who will die from bladder cancer after Robotic Surgery | Robotic surgery specific impact on survival | From enrollment to late follow-up, up to 7 years |
| Number of participants who will experience bladder cancer recurrence after Robotic Surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The study population is made up of patients who underwent radical cystectomy at AOU Careggi, SOD Robotic Urological Surgery, Minimally Invasive and Renal Transplantation.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Simone Morselli, MD | Contact | 3473050852 | simone.morselli.89@gmail.com | |
| Silvia Benemei, PhD | Contact | silvia.benemei@unifi.it |
| Name | Affiliation | Role |
|---|---|---|
| Arcangelo Sebastianelli, MD | Careggi Hospital, University of Florence | Principal Investigator |
| Sergio Serni, Prof | University of Florence | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Careggi University Hospital | Recruiting | Florence | Tuscany | 50134 | Italy |
Not provided
| ID | Term |
|---|---|
| D001749 | Urinary Bladder Neoplasms |
| D009369 | Neoplasms |
| D012008 | Recurrence |
| ID | Term |
|---|---|
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015653 | Cystectomy |
| ID | Term |
|---|---|
| D013520 | Urologic Surgical Procedures |
| D013519 | Urogenital Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided
Not provided
Not provided
Not provided
Robotic surgery specific impact on recurrence |
| From enrollment to late follow-up, up to 7 years |
| Number of participants who will experience surgical complications after Robotic Surgery | Robotic surgery specific impact on surgical complications | From enrollment to late follow-up, up to 7 years |
| Variation in Quality of Life questionnaire after Robotic Surgery | Robotic surgery specific impact on quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30) | From enrollment to late follow-up, up to 7 years |
| Variation in Quality of Life questionnaire according to Urinary diversions | Urinary diversion specific impact on quality of life according to European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30) | From enrollment to late follow-up, up to 7 years |
| Number of participants who will experience surgical complications according to Urinary diversions | Urinary diversion specific impact on surgical complications | From enrollment to late follow-up, up to 7 years |
| Number of participants who will experience bladder cancer recurrence according to Urinary diversions | Urinary diversion specific impact on bladder cancer recurrence | From enrollment to late follow-up, up to 7 years |
| Number of participants who will die from bladder cancer according to Urinary diversions | Urinary diversion specific impact on bladder cancer rmortality | From enrollment to late follow-up, up to 7 years |
| Number of participants who will die from all causes according to Urinary diversions | Urinary diversion specific impact on all cause mortality after surgery | From enrollment to late follow-up, up to 7 years |
| Simone Morselli, MD |
| University of Florence |
| Principal Investigator |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |